I’ve just read this announcement & how fantastic for us to have Prof Packham on board as CMO & also heading our medical advisory board.
His credentials are exceptional as a nephrologist, both as a physician and his 30+ years of experience in clinical trials. Welcome David if you are reading this. Sure you wouldn’t have much time lately.
Clearly Team DXB have been so busy crossing every t & dotting every i in reviewing 2a, planning & implementing trial designs & carefully choosing sites for trials & participants for 2b trials. That sounds so simple...I can just imagine the complexities, particularly the synergies between both FSGS & diabetic nephropathy trials, that was mentioned more than once in the announcement.
Really looking forward to seeing this all unfold & come to fruition in the coming months. Particularly that FSGS mostly affects kids & adolescents. They still have their whole life ahead of them, and if this can make a massive difference, all the better.
Ps we had a great time at the Sydney Royal Easter Show today.
- Forums
- ASX - By Stock
- Ann: CMO Appointment and Clinical Trials Update
I’ve just read this announcement & how fantastic for us to have...
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
35.0¢ |
Change
-0.025(6.67%) |
Mkt cap ! $25.68M |
Open | High | Low | Value | Volume |
37.0¢ | 37.0¢ | 35.0¢ | $387.8K | 1.079M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 394907 | 35.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.5¢ | 15948 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 75000 | 0.086 |
4 | 139056 | 0.085 |
2 | 158037 | 0.084 |
1 | 50000 | 0.083 |
2 | 29695 | 0.082 |
Price($) | Vol. | No. |
---|---|---|
0.087 | 1995 | 1 |
0.090 | 50000 | 1 |
0.091 | 76873 | 1 |
0.092 | 99798 | 1 |
0.093 | 50000 | 1 |
Last trade - 16.10pm 12/12/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |